The 37% increase from the prior period was mainly due to 51% growth in the global medical cannabis business and 22% growth in the plant ...

Walt Disney Co. reported first-quarter earnings as the company faces a number of challenges, despite recent box office ...

Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally ...

Q4 2024 Management View CEO Kevin Hykes highlighted strong revenue growth of $15.3 million for Q4 2024, representing a 36% increase year-over-year. U.S. Heart Failure revenues grew by 41%, supported ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

A bill introduced this legislative session aims to prohibit the sale of certain marijuana products to customers aged 21 to 25 ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...